Cytoreductive Nephrectomy Alone for mRCC Linked to Better Survival
Cytoreductive nephrectomy (CN) by itself for metastatic renal cell carcinoma is associated with a 43% decreased risk of death compared with CN plus targeted therapy.
Kidney Cancer
Partial Nephrectomy Preferable for T1a RCC
In a population-based study, PN was associated with improved cancer-specific survival by 56%.
Cancer Survivors Have High Prevalence of Chronic Pain
Prevalence higher for those with less than high school education, low income, public insurance
Study Reveals Lower Predictive Ability for Renal Cancer Models
Prospective validation shows decrease in predictive ability compared with previous retrospective validations
PN, RN Offer Comparable Long-Term Survival for T1b RCC
In a meta-analysis, partial and radical nephrectomy were associated with similar long-term overall survival, but cancer-specific survival was better with radical nephrectomy.
Combination of ICIs and Cytoreductive Surgery in Metastatic RCC Appears Promising
The expression of interferon-related genes in tumor specimens was associated with response to neoadjuvant immune checkpoint inhibitor-based therapy.
Benefit Seen from Frontline Pembrolizumab Plus Axitinib in Patients With Intermediate- or Poor-Risk Advanced RCC
Efficacy benefits of pembrolizumab plus axitinib over sunitinib were also observed in patients with disease characterized by sarcomatoid features.
Combo Shows Promise in Advanced RCC With Brain Metastases
Nivolumab plus ipilimumab, both checkpoint inhibitors, exhibit promising anti-tumor activity in patients with advanced renal cell carcinoma with brain metastases, researchers report.
Checkpoint Inhibitor-Based Combination Prolonged Progression in RCC
No overall survival benefit has yet been seen with the regimen in RCC.
Rise in TSH: A Prognostic Indicator in Sunitinib-Treated Metastatic RCC?
In this study, more than 40% of patients with metastatic RCC showed signs of hypothyroidism following 2 weeks of treatment with sunitinib.
Next post in Kidney Cancer
